NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

LifeSci Capital analyst Anshul Dhankher maintained a Buy rating on Perspective Therapeutics (CATX – Research Report ... The company has shown consistent execution in its clinical programs, ...

Additional member institutions will be announced and onboarded in subsequent phases. “The velocity of AI innovations ... we translate discovery into application and interconnect clinical care, ...

Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report ... based on EyePoint Pharmaceuticals’ notable advancements in their clinical trials and ...

biomodal, an omics-based life sciences technology and analytics company, today announced it will present new data highlighting the utility of duet mul ...

For instance, AI algorithms can rapidly screen millions of compounds, significantly speeding up the initial phases of drug ..